Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.
Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.
In a randomized crossover phase 1 study, the investigational SSTR2 antagonist ZT-01 increased glucagon responses during insulin-induced hypoglycaemia in adults with type 1 diabetes without treatment-related safety signals.
In 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.
In a retrospective cohort of pregnancies complicated by type 2 diabetes, gestational weight gain under 5 kg was associated with lower odds of several adverse perinatal outcomes without a statistically significant rise in preterm birth or sm
In adults with early type 2 diabetes inadequately controlled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, body weight, and waist circumference than intensified conventional care, with substantially higher rates of
In early type 2 diabetes uncontrolled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, weight, and waist circumference than intensified conventional care, with more patients achieving normoglycemia.
Surgical therapy for diabetic gastroparesis was linked to better long-term HbA1c control, less insulin use, and fewer diabetes-related complications, though mortality was unchanged.
In a large single-center cohort, Graves’ disease patients with preoperative TSH ≥10.0 μIU/mL had greater blood loss, larger preoperative thyroid enlargement, and longer operations, suggesting that avoiding iatrogenic hypothyroidism during s
Across four national cohorts, younger adults with type 2 diabetes had higher adiposity and triglycerides, while glycemia peaked in midlife and blood pressure and albuminuria rose with age, suggesting age-specific pathways to diabetes compli
In the Raine Study, adolescents with both MASLD and PCOS had a substantially worse cardiometabolic profile by age 27 than peers with either condition alone, highlighting a high-risk subgroup that may warrant earlier metabolic surveillance.
A prespecified CIRCUIT analysis found that Control-IQ closed-loop insulin delivery improved intrapartum time in range and reduced early postpartum hypoglycemia versus standard care in women with type 1 diabetes, without new safety concerns.
Higher insulin resistance before pregnancy was linked to poorer ovulation, lower pregnancy and live-birth rates, and more gestational diabetes in women with PCOS. Improving insulin resistance during treatment was associated with better preg
A prospective cohort study suggests that differentiated thyroid cancer patients with sustained excellent response after at least 5 years of specialist follow-up can be safely transitioned to primary care with very low recurrence risk.
In a randomized crossover trial, short-term duodenal r-RORDEP1 infusion was well tolerated and produced early changes in GLP-1, GIP, insulin, C-peptide, glucose, and a measure of insulin sensitivity in healthy men.
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip
A six-week native GIP infusion did not improve glucose control in type 2 diabetes, either alone or added to semaglutide, despite raising circulating GIP levels.
Oral semaglutide improved multiple cardiovascular risk factors in high-risk type 2 diabetes, including HbA1c, weight, systolic blood pressure, inflammation, and some lipid measures, with benefits sustained over nearly four years.
Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st
Open language-specific specialty feeds and department pages.